NISSAN
As an official partner of the Cannes Lions International Festival of Creativity, Nissan is showcasing its intelligent mobility technology to demonstrate how its innovative, zero emission range can contribute to a cleaner, quieter, future transportation network.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160629005858/en/
More than 360 delegates have taken advantage of Nissan’s shuttle service at the event, comprising of 15 Nissan LEAFs and e-NV200s, along the Boulevard de la Croisette.
In Europe, noise pollution, particularly in towns and cities, is a growing problem and has been linked with health problems. According to the European Environment Agency (EEA), more than 125 million people across Europe are currently exposed to noise levels of 55 dB or more[1] .
The running noise of a Nissan LEAF powertrain is just 21 dB[2] – less than a ceiling fan (26 dB) and way below the World Health Organisation's night time noise target for Europe (40dB)[3] . At low speed, in a city driving mode, Nissan’s electric vehicles are almost 50 percent quieter than current traditional petrol and diesel cars. This means mass adoption of EVs could significantly contribute to improving noise pollution in Europe’s cities.
Delegates were able to order a shuttle through Facebook Messenger using the search term ‘My electric ride’ and could share their selfie moments from inside the vehicles using #NissanElectric. Each shuttle wore the slogan ‘Silence is Golden’, highlighting how Nissan’s electric vehicles (EVs) can contribute to reducing noise pollution in urban areas with their almost silent powertrains.
Gareth Dunsmore, Director of Electric Vehicles for Nissan Europe, said: “We are delighted to be an official partner of this event, which gives us a fantastic opportunity to show an international audience the true potential of our zero emission technology. The Cannes Lions Festival is all about innovation, purpose and creativity – values which are at the heart of everything Nissan does. We are dedicated to providing intelligent, sustainable mobility solutions for all, and the Nissan LEAF is the ultimate embodiment of this purpose.”
“Our EVs offer a whole range of benefits which can improve the lives of our customers. Not only do they make drivers’ lives easier, offering spaciousness, quality and up to 250 km* of range on a single charge, they also contribute to improving air quality and reducing noise pollution.”
On the 23rd June, as part of the Festival, Nissan conducted a ‘silent interview’ with record-breaking free-diver, Guillaume Néry, from within a Nissan e-NV200. Fans were able to send their questions in via Nissan’s social media channels.
An eye-catching Nissan Half LEAF is also on display in the Main Square throughout the Festival. The Half LEAF is a bisected Nissan LEAF revealing to festival-goers the inner mechanics and electronics of the popular electric passenger car.
Nissan has played a pioneering role in bringing zero emission technology to the commercial mass-market. In 2010, the introduction of the Nissan LEAF – the first mass-market, pure EV launched globally – revolutionised the motoring world. It remains the best-selling EV in history, with over 224,000 LEAF units sold worldwide. Nissan followed this with the introduction of a 100 percent pure electric commercial van, the Nissan e-NV200, in 2014.
For more information about Nissan products, services and the brand’s commitment to sustainable, intelligent mobility, visit http://www.nissan.eu/experience-nissan.html .
-ENDS-
*NEDC (New European Driving Cycle) figure
NOTES TO EDITORS:
ABOUT NISSAN IN EUROPE
Nissan has one of the most
comprehensive European presences of any overseas manufacturer, employing
more than 17,000 staff across locally-based design, research &
development, manufacturing, logistics and sales & marketing operations.
Last year Nissan plants in the UK, Spain and Russia produced more than
635,000 vehicles including award-winning crossovers, commercial vehicles
and the Nissan LEAF, the world’s most popular electric vehicle. Pursuing
a goal of zero emissions and zero fatalities on the road, Nissan
recently announced its Intelligent Mobility vision. Designed to guide
Nissan’s product and technology pipeline, this 360 degree approach to
the future of mobility will anchor critical company decisions around how
cars are powered, how cars are driven, and how cars integrate into
society. Nissan is positioned to become the most desirable Asian brand
in Europe.
http://www.newsroom.nissan-europe.com
[1]
http://www.eea.europa.eu/publications/noise-in-europe-2014
[2]
http://newsroom.nissan-europe.com/EU/en-gb/Media/Media.aspx?mediaid=118084
[3]
http://www.euro.who.int/en/health-topics/environment-and-health/noise/policy/who-night-noise-guidelines-for-europe
View source version on businesswire.com: http://www.businesswire.com/news/home/20160629005858/en/
Contact:
Nissan Europe
Cedric Ratinaud
CRatinaud@nissan-europe.com
or
Yesica
Romeo
Yromeo@nissan-europe.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SINOVAC Announces Record and Distribution Dates for Special Cash Dividend30.4.2025 08:00:00 CEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that a special dividend of US$55.00 per common share, as previously announced on April 1, 2025, will be paid in cash to valid holders of SINOVAC’s common shares as of the close of business on May 23, 2025, ET. Such cash dividend is expected to be paid on or about July 9, 2025. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalificat
SES: Q1 2025 Results30.4.2025 07:30:00 CEST | Press release
Solid Start to the Year SES S.A. announces financial results for the three months ended 31 March 2025. Revenue of €509 million (-0.5% yoy(1)) and Adjusted EBITDA(2) of €280 million (-0.9% yoy(1)), both growing excl. periodic impact Networks revenue up +8.4% yoy(1) including some periodic impact supported by growth in Government (+13.1% yoy(1)) and Mobility (+8.5% yoy(1)); Media (-10.6% yoy(1)) in-line with expectations €360 million of new business and contract renewals signed in Q1 2025 Net Leverage at 1.2x(3) (including cash & cash equivalents of €3.1 billion(4)) O3b mPOWER satellites 7&8 have reached final orbital position – boosting mPower network capacity and resilience from May FY 2025 financial outlook(5) on track with yoy stable Revenue and broadly stable Adjusted EBITDA re-affirmed Fully funded Intelsat acquisition anticipated to complete in H2 2025 – intention to optimise the combined debt structure On 3 April 2025, AGM approved all company recommended resolutions including pr
Geoswift Launches Visa Direct to Enhance Cross-Border Payment Offers in Over 30 Countries30.4.2025 03:00:00 CEST | Press release
Geoswift announced today the integration of Visa Direct with Geoswift's cross-border payments platform. Visa Direct facilitates payouts to more than 140 countries and territories. The integration will enable payouts in 32 countries and territories, across 13 currencies, covering major markets in Asia Pacific, North America, Europe and Middle East, with plans for more in the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423288249/en/ Bryan Ma, SVP, Head of Geoswift Global Payments, and Swapnil Mhasde, Head of Visa Direct Commercialization and Solutions, Asia Pacific, celebrating the launch in Singapore. Geoswift is a leading provider of cross-border payment services and solutions globally. With over two decades of innovation, it has become a trusted name in B2B, education, eCommerce, remittance, and travel payment use cases. Raymond Qu, Group CEO of Geoswift, stated, "At Geoswift, our vision has always been to del
Logitech Announces Q4 and Full Fiscal Year 2025 Results29.4.2025 22:03:00 CEST | Press release
A Year of Broad-Based Sales Growth, Expanded Market Share and Increased Profitability, Driven by Strategic Priorities SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2025 ended March 31, 2025. For Fiscal Year 2025: Sales were $4.55 billion, up 6 percent in US dollars and 7 percent in constant currency, compared to the prior year. GAAP operating income was $655 million, up 11 percent compared to the prior year. Non-GAAP operating income was $775 million, up 11 percent compared to the prior year. GAAP earnings per share (EPS) was $4.13, up 7 percent compared to the prior year. Non-GAAP EPS was $4.84, up 14 percent compared to the prior year. Cash flow from operations was $843 million. The year-ending cash balance was $1.5 billion. The Company returned $797 million of cash to shareholders through its annual dividend payment and share repurchases.
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene29.4.2025 21:32:00 CEST | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC’s (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) that were challenged by BeiGene in a post-grant review (PGR) proceeding. On November 1, 2023, BeiGene filed a PGR petition with the USPTO challenging the validity of certain claims of the ‘803 patent, in response to a patent infringement lawsuit Pharmacyclics brought against BeiGene concerning BRUKINSA® (zanubrutinib). On May 1, 2024, the USPTO granted BeiGene’s petition to institute the PGR. The USPTO’s Final Written Decision is appealable by Pharmacyclics. Commenting on the ruling, BeiGene General Counsel Chan Lee said: “We are pleased that the USPTO invalidated all challenged claims of the ‘803 patent. Today’s decision reinforces our belief th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom